Adding intraperitoneal paclitaxel to intravenous paclitaxel and oral S-1 improved survival in patients with gastric cancer and peritoneal metastasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback